Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$25.84 -1.64%

-$0.38 today

Market cap
$1.80B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 0.57M

Average 0.71M

ZYME EBITDA Margin

EBITDA as a percentage of revenue.

Zymeworks Inc.NASDAQ: ZYME

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 70.8%

EBITDA Margin was 70.8% in Q3 FY2026, up 127.6 pp from a year earlier. On a trailing-twelve-month basis it was 21.5%, up 61.6 pp year over year. Over 3 fiscal years it narrowed by 99.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 45.1% for the fiscal year ending Dec 2026, up from -64.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
70.8%+1015.0 pp QoQ
Last fiscal yearDec 2025
-64.8%+77.6 pp YoY
LTMSep 2026
21.5%+61.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+127.6 pp+1516.0 pp+1388.4 pp
1 year+77.6 pp+109.9 pp+32.3 pp
3 years-99.3 pp+75.6 pp+175.0 pp
5 years+110.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-64.8%
Year-over-year change
+77.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 EBITDA Margin of 21.5% is the 3rd highest of the 10 companies compared; the peer median is -117.7%.
  • Its year-over-year change of +61.6 pp is the 3rd highest of 9, against a peer median of -26.5 pp.
  • Over three fiscal years its change of -99.3 pp compares with a peer median of +89.7 pp.
ZYME Competitors Peer median
EBITDA Margin for ZYME and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202648.0% +82.8 pp+491.0 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
ZYMEZymeworks Inc.LTM Sep 202621.5% +61.6 pp-99.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
XNCRXencor, Inc.LTM Jun 2026-117.7% -51.9 pp-9.6 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-162.2% -191.7 pp+161.5 pp
CBIOCrescent Biopharma, Inc.LTM Mar 2026-1336.8% —+61547.4 pp
IMNMImmunome, Inc.FY2025-3017.4% -1343.3 pp—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-272652.7% -264146.9 pp-12607.1 pp
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding ZYME) -117.7%-26.5 pp+89.7 pp

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue26.68M412.48M76.01M76.3M105.97M
Cost of Revenue00142.99M00
Gross Profit26.68M412.48M(66.98M)76.3M105.97M
Gross Margin100.0%100.0%-88.1%100.0%100.0%
Research & Development199.75M208.6M143.62M134.62M137M
Selling, General & Admin42.6M73.4M70.4M61.5M61.5M
Operating Expenses242.31M281.95M71.08M213.41M198.5M
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
EBITDA(206.09M)142.49M(120.7M)(108.62M)(68.64M)
EBITDA Margin-772.4%34.5%-158.8%-142.4%-64.8%
Operating Income(215.63M)130.53M(138.05M)(137.11M)(92.54M)
Operating Margin-808.2%31.6%-181.6%-179.7%-87.3%
Interest Income1.97M3.6M19.71M19.94M13.35M
Interest Expense00000
Other Income / Expenses3.27M4.71M18.81M20.5M12.78M
Income Before Tax(212.36M)135.23M(119.24M)(116.61M)(79.75M)
Pre-Tax Margin-795.9%32.8%-156.9%-152.8%-75.3%
Income Tax Expense(516K)10.89M(568K)6.08M1.38M
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Net Margin-794.0%30.1%-156.1%-160.8%-76.6%
EPS (Basic)(4.06)1.91(1.72)(1.62)(1.08)
EPS (Diluted)(4.61)1.90(1.72)(1.62)(1.08)
Weighted Avg Shares52.13M65.19M68.86M75.85M75.34M
Weighted Avg Shares (Diluted)52.13M65.25M68.86M75.88M75.34M

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$25.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.